News

HeartBeam Completes Enrollment Ahead Of Schedule In 486-Patient HEADSTART-ACS Study

HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million peopleData analysis is

Benzinga·04:40BEAT

HeartBeam Named Contributing Partner In Launch Of EXIT-CVD Research Project, Co-Funded By European Union Innovative Health Initiative And Industry Partners

HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortiumHeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studiesHEART-CHECK

Benzinga·04:37BEAT

HeartBeam stock soars on FDA breakthrough designation

Investing.com -- Heartbeam Inc (NASDAQ:BEAT) shares surged as much as 90% Monday after the company announced the U.S. Food and Drug Administration granted Breakthrough Device Designation for its at-home heart attack assessment tool.

Yahoo·11:05BEAT

HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment

The designation gives HeartBeam prioritized FDA interaction as it prepares a pivotal study of its 3D ECG technology for assessing suspected heart attacks outside traditional medical settings. Key Investor TakeawaysHeartBeam (NASDAQ:BEAT) received FDA Breakthrough Device Designation for using its 3D ECG technology to assess potential heart attacks at home.

Yahoo·10:20BEAT

HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System

HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.

Benzinga·09:46BEAT

HeartBeam Receives FDA Breakthrough Device Designation For Its HeartBeam System For Assessing Potential Heart Attacks At Home

The designation recognizes the potential of HeartBeam’s 3D ECG technology, which captures the heart’s electrical signals from three non-coplanar dimensions, to enable physicians to evaluate signs of a possible heart

Benzinga·04:35BEAT

HC Wainwright & Co. Downgrades HeartBeam to Neutral

HC Wainwright & Co. analyst Yi Chen downgrades HeartBeam (NASDAQ:BEAT) from Buy to Neutral.

Benzinga·07:53BEAT

HeartBeam, Inc. Letter to Shareholders

SANTA CLARA, Calif., September 21, 2026--HeartBeam, Inc. Letter to Shareholders

Yahoo·08:31BEAT

HeartBeam Enters ATM Equity Offering Agreement To Sell Up To $25M Of Common Stock Through Titan Partners Securities

On August 14, 2026, HeartBeam, Inc. (the "Company"), entered into an At-The-Market Equity Offering Sales Agreement (the "Sales Agreement") with Titan Partners Securities LLC, as sales agent, pursuant to

Benzinga·13:07BEAT

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call August 13, 2026 4:30 PM EDTCompany ParticipantsRichard Ferrari - Executive ChairmanTimothy Cruickshank - Chief...

SeekingAlpha·22:47BEAT

HeartBeam Reports Q2 2026 Results: Full Earnings Call Transcript

HeartBeam (NASDAQ:BEAT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial

Benzinga·13:35BEAT

HeartBeam, Inc. 2026 Q2 - Results - Earnings Call Presentation

2026-08-13. The following slide deck was published by HeartBeam, Inc.